These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. Foulds PG; Yokota O; Thurston A; Davidson Y; Ahmed Z; Holton J; Thompson JC; Akiyama H; Arai T; Hasegawa M; Gerhard A; Allsop D; Mann DM Neurobiol Dis; 2012 Jan; 45(1):188-95. PubMed ID: 21856424 [TBL] [Abstract][Full Text] [Related]
3. Alpha-Synuclein Protofibrils in Cerebrospinal Fluid: A Potential Biomarker for Parkinson's Disease. von Euler Chelpin M; Söderberg L; Fälting J; Möller C; Giorgetti M; Constantinescu R; Blennow K; Zetterberg H; Höglund K J Parkinsons Dis; 2020; 10(4):1429-1442. PubMed ID: 33016895 [TBL] [Abstract][Full Text] [Related]
4. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. Magdalinou NK; Paterson RW; Schott JM; Fox NC; Mummery C; Blennow K; Bhatia K; Morris HR; Giunti P; Warner TT; de Silva R; Lees AJ; Zetterberg H J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1240-7. PubMed ID: 25589779 [TBL] [Abstract][Full Text] [Related]
5. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes. Constantinides VC; Paraskevas GP; Emmanouilidou E; Petropoulou O; Bougea A; Vekrellis K; Evdokimidis I; Stamboulis E; Kapaki E J Neurol Sci; 2017 Nov; 382():91-95. PubMed ID: 29111028 [TBL] [Abstract][Full Text] [Related]
6. Systematic Assessment of 10 Biomarker Candidates Focusing on α-Synuclein-Related Disorders. Schulz I; Kruse N; Gera RG; Kremer T; Cedarbaum J; Barbour R; Zago W; Schade S; Otte B; Bartl M; Hutten SJ; Trenkwalder C; Mollenhauer B Mov Disord; 2021 Dec; 36(12):2874-2887. PubMed ID: 34363416 [TBL] [Abstract][Full Text] [Related]
7. Combined CSF α-SYN RT-QuIC, CSF NFL and midbrain-pons planimetry in degenerative parkinsonisms: From bedside to bench, and back again. Compta Y; Painous C; Soto M; Pulido-Salgado M; Fernández M; Camara A; Sánchez V; Bargalló N; Caballol N; Pont-Sunyer C; Buongiorno M; Martin N; Basora M; Tio M; Giraldo DM; Pérez-Soriano A; Zaro I; Muñoz E; Martí MJ; Valldeoriola F Parkinsonism Relat Disord; 2022 Jun; 99():33-41. PubMed ID: 35594661 [TBL] [Abstract][Full Text] [Related]
8. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia. Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675 [TBL] [Abstract][Full Text] [Related]
9. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042 [TBL] [Abstract][Full Text] [Related]
10. Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease. Parnetti L; Farotti L; Eusebi P; Chiasserini D; De Carlo C; Giannandrea D; Salvadori N; Lisetti V; Tambasco N; Rossi A; Majbour NK; El-Agnaf O; Calabresi P Front Aging Neurosci; 2014; 6():53. PubMed ID: 24744728 [TBL] [Abstract][Full Text] [Related]
11. Plasma Biomarkers Differentiate Parkinson's Disease From Atypical Parkinsonism Syndromes. Lin CH; Yang SY; Horng HE; Yang CC; Chieh JJ; Chen HH; Liu BH; Chiu MJ Front Aging Neurosci; 2018; 10():123. PubMed ID: 29755341 [No Abstract] [Full Text] [Related]
12. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis. Sako W; Murakami N; Izumi Y; Kaji R Mov Disord; 2014 Nov; 29(13):1599-605. PubMed ID: 25258345 [TBL] [Abstract][Full Text] [Related]
13. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882 [TBL] [Abstract][Full Text] [Related]
14. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders. Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721 [TBL] [Abstract][Full Text] [Related]
15. The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology. Førland MG; Tysnes OB; Aarsland D; Maple-Grødem J; Pedersen KF; Alves G; Lange J Eur J Neurol; 2020 Jan; 27(1):43-50. PubMed ID: 31293044 [TBL] [Abstract][Full Text] [Related]
16. The Diagnostic and Differential Diagnosis Utility of Cerebrospinal Fluid α -Synuclein Levels in Parkinson's Disease: A Meta-Analysis. Zhou B; Wen M; Yu WF; Zhang CL; Jiao L Parkinsons Dis; 2015; 2015():567386. PubMed ID: 26336612 [TBL] [Abstract][Full Text] [Related]
17. Alpha-Synuclein species in oral mucosa as potential biomarkers for multiple system atrophy. Zheng Y; Cai H; Zhao J; Yu Z; Feng T Front Aging Neurosci; 2022; 14():1010064. PubMed ID: 36304930 [TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid and plasma distribution of anti-α-synuclein IgMs and IgGs in multiple system atrophy and Parkinson's disease. Folke J; Rydbirk R; Løkkegaard A; Hejl AM; Winge K; Starhof C; Salvesen L; Pedersen LØ; Aznar S; Pakkenberg B; Brudek T Parkinsonism Relat Disord; 2021 Jun; 87():98-104. PubMed ID: 34020303 [TBL] [Abstract][Full Text] [Related]
19. Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis. Eusebi P; Giannandrea D; Biscetti L; Abraha I; Chiasserini D; Orso M; Calabresi P; Parnetti L BMJ Open; 2016 Jun; 6(6):e011113. PubMed ID: 27297011 [TBL] [Abstract][Full Text] [Related]